Puma Biotechnology | PBYI - Себестоимость





Себестоимость Изменить Дата
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amgen USD 1.6B 187M 2026-03
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Daiichi Sankyo JPY 118.28B 37.7B 2025-12
Esperion Therapeutics USD 27.85M 13.43M 2025-12
Exelixis USD 26.48M 7.91M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
Glaxosmithkline GBP 3.47B 461.37M 2025-12
Incyte USD 104.5M 16.68M 2026-03
MacroGenics USD 10.12M 34.18M 2025-12
Moderna USD 955M 503M 2026-03
Novartis USD 3.46B 83M 2026-03
Pfizer USD 6.29B 2.12B 2025-12
PTC Therapeutics USD 16.3M 7.02M 2025-12
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sangamo BioSciences 2.42M 1.11M 2024-06
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Takeda JPY 401.15B 184.07B 2025-12
TG Therapeutics USD 38.14M 10.05M 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03